Foie | Nano Publications

2018 – ASTRO – NBTXR3 in solid tumors

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

To improve radiotherapy (RT) in terms of tumor response and to reduce irradiation of healthy tissues, innovative therapeutic approaches are needed. In response, NBTXR3, injectable hafnium oxide nanoparticles, was developed for the treatment of solid tumors. Once injected intratumorally, NBTXR3 can deposit high energy within tumors only when activated by an ionizing radiation source, like current standard RTs. […]

Continuer la lecture…

2018-ASTRO 2018- NBTXR3 in liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

Radiation oncology technological development is principally focused in improving the precision of radiotherapy (RT) and reducing unwanted irradiation to normal tissues. There is an unmet medical need into ameliorating the energy dose deposit within tumor cells without increasing the dose received by surrounding healthy tissues. […]

Continuer la lecture…

2018 – ESMO – NBTXR3 in HCC and Liver Metastasis

Abstracts, Donnée clinique de NBTXR3, Foie, Tête & Cou

For patients (pts) with hepatocellular carcinoma (HCC) or liver metastasis (liver mets), stereotactic body radiation therapy (SBRT) is a well-tolerated option. Yet, the risk of injury to normal tissues limits the ability to efficiently sterilize tumor cells. Thus, hafnium oxide nanoparticles, NBXTR3, were developed, which increase the interaction of radiotherapy energy dose deposition within tumor cells when activated by an ionizing energy source like SBRT. […]

Continuer la lecture…

2018 – ASCO – NBTXR3 in the treatment of liver cancer: a phase I/II trial

Abstracts, Donnée clinique de NBTXR3, Foie

With recent advances in radiation delivery techniques, an increasing number of cancer patients undergo radiotherapy. However, due to the non-targeted nature of radiotherapy, doses are limited by potential toxicity to surrounding normal tissue. Thus, a major challenge remains to develop new strategies to improve the tumor selectivity of radiation therapy. […]

Continuer la lecture…

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

Continuer la lecture…

2018 – ESMO 2018 – NBTXR3 in elderly HNSCC

Abstracts, Donnée clinique de NBTXR3, Foie

Elderly patients (pts) with head and neck squamous cell carcinoma (HNSCC) represent 25% of the affected population. They are not always eligible to the same treatment of younger pts, thus require new therapies. NBTXR3, injectable hafnium oxide nanoparticles activated by radiotherapy (RT), was developed to increase the local deposit of energy within the tumor. […]

Continuer la lecture…

2018 – ESTRO – Hafnium Oxide Nanoparticles and Radiotherapy: A Promising New Treatment Strategy

Abstracts, Donnée clinique de NBTXR3, Foie, Rectum, STM, Tête & Cou

Continuer la lecture…

2018 – ESMO WGI – NBTXR3 in HCC and Liver Mets

Abstracts, Donnée clinique de NBTXR3, Foie

Management of hepatocellular carcinoma (HCC) and liver metastasis (mets) requires complementary expertise of multiple specialties. Treatment decisions are increasingly complex and physicians must face a wide range of underlying liver dysfunctions and concomitant malignancies. Among available treatments, stereotactic body radiation therapy (SBRT) is well-tolerated. […]

Continuer la lecture…

2018 – ASCO GI – A phase I/II trial of NBTXR3 nanoparticles activated by SBRT in the treatment of liver cancers

Abstracts, Donnée clinique de NBTXR3, Foie

The physical mode of action of NBTXR3 may represent a breakthrough approach for the local treatment of liver cancers, as it does not engage liver and renal functions, i.e. nanoparticles are not metabolized and not excreted by kidney. A phase I/II trial has been implemented for the treatment of hepatocellular carcinoma and liver metastasis. […]

Continuer la lecture…